Achieving a better cure for cancer

More info


CiMaas develops immunotherapy for cancer by optimally engaging the immune system.

Read more about CiMaas Immunotherapy products,
or watch our video.

News /

CiMaas featured in Brightlands media campaign

The national campaign - to the end of June 2019 - airs radiospots and runs advertisements in several national newspapers to draw attention to the collaboration between the University and Brightlands in developing solutions for important societal issues. CiMaas regenerates the immune system to fight cancer.

News /

CiMaas obtains gene therapy classification from EMA for its’ DC vaccine

Upon a recent application and discussion with EMA, Cimaas received the classification for its' dendritic cell vaccine. EMA/CAT considers that the WT1-DC-Xcite-L1 falls within the definitions of a somatic cell therapy medicinal product and a gene therapy medicinal product and based on that is considered as gene therapy medicinal product as provided in Article 2(5) of Regulation (EC) No 1394/2007.